Aura Biosciences, Inc. — Director's Dealing 2021

Oct 28, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Aura Biosciences, Inc. (AURA)
CIK: 0001501796
Period of Report: 2021-10-28

Reporting Person: Johnson David Michael (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series E Convertible Preferred Stock	$		Common Stock (139672)		Indirect
Stock Option (Right to Buy)	$4.38	2030-12-14	Common Stock (116788)		Direct
Stock Option (Right to Buy)	$5.48	2031-06-28	Common Stock (204379)		Direct

Footnotes

F1: Immediately prior to the completion of the Issuer's initial public offering, each share of Series E Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock, on a 13.7-for one basis and has no expiration date.

F2: Upon the closing of the Issuer's initial public offering, all shares of Series E Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 3.

F3: Velosity Capital Management LLC is an entity that the reporting person is the sole member of.

F4: The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months following December 8, 2020.

F5: The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months following March 18, 2021.